WO2018085363A3 - Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma - Google Patents

Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma Download PDF

Info

Publication number
WO2018085363A3
WO2018085363A3 PCT/US2017/059487 US2017059487W WO2018085363A3 WO 2018085363 A3 WO2018085363 A3 WO 2018085363A3 US 2017059487 W US2017059487 W US 2017059487W WO 2018085363 A3 WO2018085363 A3 WO 2018085363A3
Authority
WO
WIPO (PCT)
Prior art keywords
multiple myeloma
prognostic
diagnostic
detection
monitoring methods
Prior art date
Application number
PCT/US2017/059487
Other languages
French (fr)
Other versions
WO2018085363A2 (en
Inventor
James Richard BERENSON
Original Assignee
Berenson James Richard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berenson James Richard filed Critical Berenson James Richard
Publication of WO2018085363A2 publication Critical patent/WO2018085363A2/en
Publication of WO2018085363A3 publication Critical patent/WO2018085363A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention generally provides improved compositions and methods for detecting, diagnosing, prognosing, and monitoring a hematological malignancy in a subject. More specifically, the invention provides methods for detecting CD147 in subjects to diagnose, predict survival and/or monitor progression of a hematological malignancy, particularly a multiple myeloma, in a subject.
PCT/US2017/059487 2016-11-02 2017-11-01 Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma WO2018085363A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416601P 2016-11-02 2016-11-02
US62/416,601 2016-11-02

Publications (2)

Publication Number Publication Date
WO2018085363A2 WO2018085363A2 (en) 2018-05-11
WO2018085363A3 true WO2018085363A3 (en) 2018-12-20

Family

ID=62076650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/059487 WO2018085363A2 (en) 2016-11-02 2017-11-01 Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma

Country Status (1)

Country Link
WO (1) WO2018085363A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2900529A1 (en) 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
US11698369B2 (en) 2016-01-12 2023-07-11 Oncotracker, Inc. Methods for monitoring immune status of a subject

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046244A1 (en) * 2014-09-23 2016-03-31 Klinikum Rechts Der Isar Der Tu München Method for assessing the efficacy of imids and composition or combination for use in treating imid sensitive diseases
WO2016054354A1 (en) * 2014-10-02 2016-04-07 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046244A1 (en) * 2014-09-23 2016-03-31 Klinikum Rechts Der Isar Der Tu München Method for assessing the efficacy of imids and composition or combination for use in treating imid sensitive diseases
WO2016054354A1 (en) * 2014-10-02 2016-04-07 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies

Also Published As

Publication number Publication date
WO2018085363A2 (en) 2018-05-11

Similar Documents

Publication Publication Date Title
MX367046B (en) Pathway specific markers for diagnosing irritable bowel syndrome.
EA201290711A1 (en) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PREDICTION OF KIDNEY DAMAGE AND RENAL FAILURE
EA201590027A1 (en) DETECTION METHODS OF DISEASES OR CONDITIONS
MX351779B (en) PREDICTING GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASMS (GEP-NENs).
WO2016044338A3 (en) Methods and systems for diagnosing sleep disorders
MX350533B (en) Pancreatic cancer biomarkers and uses thereof.
EA201390149A1 (en) METHODS FOR DETECTING DISEASES OR PATHOLOGICAL CONDITIONS USING PHAGOCYTARY CELLS
WO2014160275A3 (en) Biomarkers for liver fibrosis
MX336280B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
MX2021012347A (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm.
MY175351A (en) Method and kit for measurement of nk cell activity
EA201500080A1 (en) METHOD IN VITRO DIAGNOSIS AND MONITORING OF CANCER
WO2016064877A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2015010174A (en) Diagnostic tools to predict onset of preeclampsia.
MX2016004167A (en) Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease.
MX358474B (en) Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases.
WO2016089732A3 (en) Methods and compositions for diagnosis and management of diabetes and metabolic syndrome
WO2018085363A3 (en) Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma
WO2017029401A8 (en) Means and methods for diagnosing cardiac disease in a subject
WO2011130647A3 (en) Compositions and methods for characterizing a myopathy
WO2018187385A8 (en) Compositions and methods of diagnosing pancreatic cancer
WO2012016216A3 (en) Assays for detection of glycosaminoglycans
AU2010209763A8 (en) Biomarker for diagnosis, prediction and/or prognosis of acute heart failure and uses thereof
WO2013116677A3 (en) Assays for detection of glycosaminoglycans
WO2014008273A3 (en) Methods for treating, diagnosing and/or monitoring progression of oxo associated states

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17868300

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17868300

Country of ref document: EP

Kind code of ref document: A2